Effects of direct-acting antiviral agents on lipid and glucose profile in HCV patients with type 2 diabetes: A real-life Italian experience.
cardiovascular risk factors
direct-acting antiviral agents
glucose profile
hepatitis C virus
lipid profile
type 2 diabetes mellitus
Journal
Journal of digestive diseases
ISSN: 1751-2980
Titre abrégé: J Dig Dis
Pays: Australia
ID NLM: 101302699
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
revised:
09
06
2022
received:
10
10
2021
accepted:
10
06
2022
pubmed:
15
6
2022
medline:
18
8
2022
entrez:
14
6
2022
Statut:
ppublish
Résumé
Hepatitis C virus (HCV) infection is associated with an increased risk of type 2 diabetes mellitus (T2DM) and cardiovascular diseases. The impact of HCV eradication on the metabolic profile in diabetic patients treated with direct-acting antiviral agents (DAAs) is not well defined. The aim of our study was to evaluate the effects of DAAs on a lipid and glucose profile in a cohort of diabetic patients with different liver fibrotic stages. T2DM patients with active HCV infection were consecutively enrolled in this prospective trial. Glycolipidic status was assessed, before starting DAA treatment (T0) and at 12 months after the beginning of treatment (T1). Liver fibrotic stage was assessed by FibroScan. In all, 131 patients were enrolled and all of them achieved a sustained virologic response. At baseline, no significant differences were found in lipid and glucose profiles in subgroup analysis by liver fibrosis, HCV genotype, and cardiovascular risk factors. At T1, total cholesterol and low-density lipoprotein cholesterol, but not triglycerides, significantly increased irrespective of liver fibrotic stage and baseline anthropometric and clinical profiles, while glycated hemoglobin significantly decreased only in F4 patients. HCV eradication in diabetic patients is associated with a worsening lipid profile that could impact future cardiovascular risk. A careful global monitoring of cardiovascular risk factors in all diabetic patients after HCV eradication is needed.
Identifiants
pubmed: 35700113
doi: 10.1111/1751-2980.13103
doi:
Substances chimiques
Antiviral Agents
0
Lipids
0
Cholesterol
97C5T2UQ7J
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
324-330Informations de copyright
© 2022 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.
Références
Manns MP, Buti M, Gane E, et al. Hepatitis C virus infection. Nat Rev Dis Prim. 2017;3:17006. https://doi.org/10.1038/nrdp.2017.6.
Serfaty L. Metabolic manifestations of hepatitis C virus: diabetes mellitus, dyslipidemia. Clin Liver Dis. 2017;21(3):475-486.
Zaki MSE. The effect of hepatitis C virus infection on cardiovascular complications in end stage kidney disease patients on regular hemodialysis. Electron Physician. 2017;9(2):3857-3861.
Kim D, Adejumo AC, Yoo ER, et al. Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017. Gastroenterology. 2019;157(4):1055-1066.e11.
Lee KK, Stelzle D, Bing R, et al. Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. Lancet Gastroenterol Hepatol. 2019;4(10):794-804.
Wernly B, Wernly S, Niederseer D, Datz C. Hepatitis C virus (HCV) infection and cardiovascular disease: hepatologists and cardiologists need to talk! Eur J Intern Med. 2020;71:87-88.
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-234.
Milicevic Z, Raz I, Beattie SD, et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care. 2008;31(Suppl):S155-S160.
Kukla M, Piotrowski D, Waluga M, Hartleb M. Insulin resistance and its consequences in chronic hepatitis C. Clin Exp Hepatol. 2015;1(1):17-29.
Cacoub P, Comarmond C. Considering hepatitis C virus infection as a systemic disease. Semin Dial. 2019;32(2):99-107.
Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(Suppl):S165-S173.
Lanini S, Scognamiglio P, Pisapia R, Minosse C, Agresta A, Ippolito G. Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. Int J Antimicrobial Agents. 2019;53(5):559-563.
Kralj D, Virović Jukić L, Stojsavljević S, Duvnjak M, Smolić M, Čurčić IB. Hepatitis C virus, insulin resistance, and steatosis. J Clin Transl Hepatol. 2016;4(1):66-75.
Bedossa P, Moucari R, Chelbi E, et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology. 2007;46(2):380-387.
Ciancio A, Bosio R, Bo S, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol. 2018;90(2):320-327.
Ziada DH, El Saadany S, Enaba M, Ghazy M, Hasan A. The interaction between insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C. Can J Gastroenterol. 2012;26(6):325-329.
Pedersen MR, Patel A, Backstedt D, Choi M, Seetharam AB. Genotype specific peripheral lipid profile changes with hepatitis C therapy. World J Gastroenterol. 2016;22(46):10226-10231.
Ikeda A, Ikeda K, Takai A, et al. Hepatitis C treatment with sofosbuvir and ledipasvir accompanied by immediate improvement in hemoglobin A1c. Digestion. 2017;96(4):228-230.
Lanini S, Bartolini B, Taibi C, et al. Early improvement of glycaemic control after virus clearance in patients with chronic hepatitis C and severe liver fibrosis: a cohort study. New Microbiol. 2019;42(3):139-144.
Chaudhury CS, Sheehan J, Chairez C, et al. No improvement in hemoglobin A1c following hepatitis C viral clearance in patients with and without HIV. J Infect Dis. 2017;217(1):47-50.
Carvalho JR, Velosa J, Serejo F. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens. Scand J Gastroenterol. 2018;53(7):857-863.
Huang JF, Huang CF, Yeh ML, et al. The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents. Kaohsiung J Med Sci. 2017;33(11):567-571.
Meissner EG, Lee YJ, Osinusi A, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015;61(3):790-801.
Kawagishi N, Suda G, Nakamura A, et al. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS One. 2018;13(12):e0209615. https://doi.org/10.1371/journal.pone.0209615.
Russo FP, Zanetto A, Gambato M, et al. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. J Viral Hepat. 2020;27(2):188-194.
Alsebaey A, Elhelbawy M, Abdel-Razek W, Hashim M, Elshenawy H, Waked I. HCV treatment with direct acting antivirals improves the insulin sensitivity. Expert Rev Anti Infect Ther. 2019;17(9):749-754.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461-511.
Davies M. New diagnostic criteria for diabetes-are they doing what they should? Lancet. 1999;354(9179):610-611.
Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.
European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264.
Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic hepatitis C association with diabetes mellitus and cardiovascular risk in the era of DAA therapy. Can J Gastroenterol Hepatol. 2018;2018:6150861. https://doi.org/10.1155/2018/6150861.
Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular carcinoma mechanisms associated with chronic HCV infection and the impact of direct-acting antiviral treatment. J Hepatocell Carcinoma. 2020;7:45-76.
Cacciola I, Russo G, Filomia R, et al. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. Liver Int. 2021;41(9):2059-2067.
Targett-Adams P, Boulant S, Douglas MW, McLauchlan J. Lipid metabolism and HCV infection. Viruses. 2010;2(5):1195-1217.
Spaziante M, Taliani G, Marchetti G, et al. Impact of HCV eradication on lipid metabolism in HIV/HCV coinfected patients: data from ICONA and HepaICONA Foundation cohort study. Viruses. 2021;13(7):1402. https://doi.org/10.3390/v13071402.
Villani R, Di Cosimo F, Romano AD, Sangineto M, Serviddio G. Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis. Sci Rep. 2021;11(1):13944. https://doi.org/10.1038/s41598-021-93251-3.
Muñoz-Cabrejas A, Espina Cadena S, Arbonés-Mainar JM, Moreno-Franco B. Lipid metabolism alterations produced by hepatitis C virus in patients with chronic infection. Rev Esp Salud Publica. 2020;94:e202005049. [in Spanish].
Ichikawa T, Miyaaki H, Miuma S, et al. Carotid intima-media thickness and small dense low-density lipoprotein cholesterol increase after one year of treatment with direct-acting antivirals in patients with hepatitis C virus infection. Intern Med. 2019;58(9):1209-1215.
Huang CF, Dai CY, Yeh ML, et al. Cure or curd: modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication. Kaohsiung J Med Sci. 2020;36(11):920-928.
Janicko M, Drazilova S, Pella D, Fedacko J, Jarcuska P. Pleiotropic effects of statins in the diseases of the liver. World J Gastroenterol. 2016;22(27):6201-6213.
Vahedian-Azimi A, Shojaie S, Banach M, et al. Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants. Ann Med. 2021;53(1):1227-1242.